Galapagos Says ‘No’ to SpinCo and Instead Will Seek Deals for All Assets
8 Articles
8 Articles
Galapagos Says ‘No’ to SpinCo and Instead Will Seek Deals for All Assets
Galapagos has dropped plans for a business separation that would have enabled the legacy company to focus exclusively on developing new cancer cell therapies. Instead, Galapagos said it will pursue strategic alternatives for its assets. The post Galapagos Says ‘No’ to SpinCo and Instead Will Seek Deals for All Assets appeared first on MedCity News.
Biotechnologist Galapagos is backtracking on a split of the company announced in January. The company listed on the Amsterdam stock exchange reports that it is reconsidering the split "in response to developments in regulations and the market". To lead this process in the right direction, Galapagos is appointing a new CEO in the person of Henry Gosebruch. He will succeed Paul Stoffels, who had previously announced his retirement.
Pharma group Galapagos picks new CEO, backtracks on spinoff - Regional Media News
(Reuters) -Pharmaceutical firm Galapagos has appointed Henry Gosebruch as its new CEO as it steers away from a plan to split into two listed entities, it said on Tuesday. The Amsterdam-listed group, headquartered in the city of Mechelen in Belgium, had said in January it planned the spinoff of its innovative medicines business to have effect by mid-2025, and that it would provide around 2.45 billion euros ($2.72 billion) of cash for the new enti…
Coverage Details
Bias Distribution
- 67% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
